Latest Breaking News On - Woodline master fund - Page 1 : comparemela.com

Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesJohn valliantAmanda crayFusion pharmaceuticals incWoodline master fundNiowave incDeerfield management companyAmerican association for cancer researchPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsInvestor relations corporate communicationsExecutive officer john valliantAvidity partnersFederated hermes kaufmann fundsPerceptive advisorsAmerican association

Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha.

United statesEbrahim delpassandJohn valliantAmanda crayFusion pharmaceuticals incMorgan stanleySpica centerDeerfield management companyLaborde professor for cancer researchPrnewswire fusion pharmaceuticals incRadiomedix incFusion pharmaceuticalsWoodline master fundNiowave incTulane cancer centerExchange commission

Fusion Pharmaceuticals (FUSN) Announces 17 6M Share Offering at $3 40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T

Fusion Pharmaceuticals (FUSN) Announces 17 6M Share Offering at $3 40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesEbrahim delpassandJohn valliantOliver sartorFusion pharmaceuticals incMorgan stanleyWoodline master fundDeerfield management companyTulane cancer centerLaborde professor for cancer researchExchange commissionDiagnostics nuclear oncology centerRadiomedix incFusion chief executive officer john valliantLaborde professorCancer research